Nvest Wealth Strategies’s Edwards Lifesciences EW Stock Holding History

Nvest Wealth Strategies’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$272	Buy	+3	New	+$251	﹤0.01%	334

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

Nvest Wealth Strategies's EW Position: Q2 2026 in Review

Nvest Wealth Strategies opened a new position in Edwards Lifesciences (EW) in Q2 2026: 3 shares worth $272. The stake represents ﹤0.01% of the portfolio and ranks #334 among its holdings.

774 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Nvest Wealth Strategies held 3 shares of Edwards Lifesciences worth $272 as of Q2 2026.
Edwards Lifesciences was a new Nvest Wealth Strategies position in Q2 2026.
Edwards Lifesciences made up ﹤0.01% of Nvest Wealth Strategies's portfolio in Q2 2026, its #334 holding.
774 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Nvest Wealth Strategies's 13F filing for Q2 2026, filed 10 Jul 2026.